Expression of the RNA component of human telemorase (hTR) in ThinPrep (R) preparations from bladder washings

Citation
A. Maitra et al., Expression of the RNA component of human telemorase (hTR) in ThinPrep (R) preparations from bladder washings, CANC CYTOP, 93(1), 2001, pp. 73-79
Citations number
31
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
CANCER CYTOPATHOLOGY
ISSN journal
0008543X → ACNP
Volume
93
Issue
1
Year of publication
2001
Pages
73 - 79
Database
ISI
SICI code
0008-543X(20010225)93:1<73:EOTRCO>2.0.ZU;2-Z
Abstract
BACKGROUND. The enzyme telomerase is associated with cellular immortality a nd is expressed in the vast majority of human neoplasms. The expression of the RNA component of human telomerase (hTR) shows excellent concordance wit h enzyme activity. METHODS. In this study, hTR expression was analyzed in a series of 18 perio perative bladder washings and compared with histologic diagnoses from mater ial obtained in the same setting. The hTR expression analysis used an S-35- based in-situ hybridization assay. ThinPrep(R) preparations fixed in Preser vCyt(R) solution (Cytyc Corporation, Boxborough, MA) were hybridized with s ense and antisense hTR probes. A 1-4+ grading scheme was used, with appropr iate positive and negative controls. RESULTS. Five of six (83%) lesions with benign histology had hTR expression that was 2+ or less in the exfoliated urothelial cells. In contrast, 11 of 12 (93%) lesions with malignant histology had an hTR expression that was f ocally 3+ or more, with 7 of 12 (58%) lesions having 4+ hTR expression in a t least some urothelial clusters. Although increased hTR expression was pre sent in smears with malignant urothelial cells, a similar trend was not see n with muscularis propria invasion or higher grades of TCC on subsequent hi stology. CONCLUSIONS. The use of in situ hybridization technique bypasses the need f or stringent specimen processing and allows identification of the specific cell type that expresses telomerase. Cancer (Cancer Cytopathol) 2001;93:73- 79. (C) 2001 American Cancer Society.